Skip to main content
TipRanks
Go Ultimate75% OFF

Morishita Jintan Co., Ltd. (4524) AI Stock Analysis

3 Followers
JP:4524

Morishita Jintan Co., Ltd.

(TSE/TYO:4524)

Select Model
Rating:62Neutral
Price Target:JPY 2,334.00â–²(5.80% Upside)
Action:downgraded
Date:11/18/26

The company's financial stability is a key strength, anchored by a very conservative balance sheet with low debt. However, this is offset by modest profitability, recent revenue softness, and minimal free cash flow due to heavy reinvestment. Technical indicators show a neutral trend, while the low P/E ratio and solid dividend yield provide some valuation support. Overall, the stock presents a stable but low-growth profile.

Positive Factors
Conservative balance sheetThe substantial equity base and historically low leverage provide financial resilience and reduce dependence on external funding. This supports continued product investment and gives Morishita Jintan more capacity to withstand operating volatility while preserving strategic flexibility.
Negative Factors
Recent revenue contractionThe 2026 revenue decline interrupts the company’s preceding expansion and could pressure operating leverage if sales remain soft. Persistent top-line weakness would limit reinvestment capacity and make it harder for stable profitability to translate into stronger absolute earnings.

Morishita Jintan Co., Ltd. (4524) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%35%JP:4524+5.40%EWJ+16.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 9.03B
Dividend Yield
2.95%
Average Volume (3M)
1,591
Price to Earnings (P/E)
10.3
Beta (1Y)
0.32
Revenue Growth
-0.47%
EPS Growth
50.82%
Country
Japan
Employees
359
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Morishita Jintan Co., Ltd. Business Overview & Revenue Model

Company Description

Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two mai...

How the Company Makes Money

Morishita Jintan generates revenue primarily by selling branded consumer healthcare products. Key revenue streams include: (1) Direct product sales: Income from the sale of its own branded health-related products (e.g., mouth/throat care items, suppl...

Morishita Jintan Co., Ltd. Financial Statement Overview

Summary

The balance sheet is very strong (Score 85) with minimal debt, but the income statement (Score 60) shows modest profitability and recent revenue decline, while cash flow (Score 50) is constrained by high capex. The overall financial picture is stable but growth and cash generation are limited.

Income Statement

60Neutral

Balance Sheet

85Very Positive

Cash Flow

50Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.82B12.69B12.77B12.41B11.36B9.56B
Gross Profit6.23B5.93B5.79B6.00B5.31B4.88B
EBITDA1.54B1.29B1.36B1.29B1.25B977.00M
Net Income789.00M628.00M547.00M697.00M491.00M283.00M
Balance Sheet
Total Assets18.62B18.62B17.90B17.18B16.10B14.48B
Cash, Cash Equivalents and Short-Term Investments1.52B1.83B1.94B1.09B2.41B2.14B
Total Debt1.75B1.76B1.36B270.00M469.00M749.00M
Total Liabilities5.65B5.64B5.74B5.04B4.71B4.02B
Stockholders Equity12.97B12.98B12.15B12.14B11.39B10.46B
Cash Flow
Free Cash Flow018.00M69.00M-455.00M715.00M-159.00M
Operating Cash Flow01.15B669.00M196.00M1.18B543.00M
Investing Cash Flow0-1.23B-701.00M-1.15B-474.00M-463.00M
Financing Cash Flow0-30.00M880.00M-362.00M-433.00M-645.00M

Morishita Jintan Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price2206.00

Price Trends

50DMA2219.54Negative
100DMA2209.46Negative
200DMA2209.89Negative

Market Momentum

MACD-3.18Negative
RSI50.29Neutral
STOCH69.37Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Positive. The current price of 2206.00 is above the 20-day moving average (MA) of 2198.05, below the 50-day MA of 2219.54, and below the 200-day MA of 2209.89, indicating a neutral trend. The MACD of -3.18 indicates Negative momentum. The RSI at 50.29 is Neutral, neither overbought nor oversold. The STOCH value of 69.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4524.

Morishita Jintan Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4524 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4540JP:454070OutperformJPY 303.35B9.289.84%3.98%13.32%17.39%
JP:4538JP:453863NeutralJPY 19.02B8.33―4.15%2.29%―
JP:4524JP:452462NeutralJPY 9.00B10.30―2.95%-0.47%50.82%
JP:2929JP:292957NeutralJPY 15.88B8.02―4.01%-3.12%406.78%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4512JP:451245NeutralJPY 10.13B56.26―1.20%23.41%149.71%

* Healthcare Sector Average

Performance Comparison

-20%0%20%JP:4524JP:4540JP:2929JP:4512JP:4538Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4524 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4524Morishita Jintan Co., Ltd.2206.00125.676.04%
JP:4540Tsumura & Co3965.00333.159.17%
JP:2929Pharma Foods International Co., Ltd.548.00-215.79-28.25%
JP:4512Wakamoto Pharmaceutical Co., Ltd.292.0020.297.47%
JP:4538Fuso Pharmaceutical Industries,Ltd.2168.0078.623.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026